Core Viewpoint - The article discusses the evolution and future prospects of China's medical investment landscape over the next decade, highlighting significant changes and opportunities in the industry, particularly in innovative pharmaceuticals and medical technology [2][3]. Summary by Sections Historical Context - The period from 2015 to 2024 marks a complete decade of development for China's innovative drug sector, with a focus on both achievements and future directions for medical investment [3]. Key Milestones in 2025 - 2025 is identified as a historic year for the medical industry, with notable events such as the emergence of Eli Lilly as the first trillion-dollar company in the healthcare sector, reflecting the industry's potential for high market valuations [4]. - The Hong Kong Stock Exchange has become a crucial platform for medical companies, achieving a financing amount of $36 billion and nearly 100 listed companies, with 10% being healthcare firms, particularly in innovative drugs [4]. - Significant business development (BD) transactions have occurred, including a landmark $1.25 billion upfront payment to 3SBio, indicating growing international recognition of Chinese innovative drug intellectual property [4]. Industry Growth and Changes - The past decade has seen a dramatic increase in clinical trial institutions from 400 to approximately 1,600, and the number of personnel in China's drug review center has risen from 100 to nearly 700, although still lagging behind the U.S. [6]. - The shift from licensing in to licensing out has transformed China's role in the global pharmaceutical market, with the country becoming the largest marketplace for innovative drugs [6][7]. Future Predictions - The article predicts that during the 14th Five-Year Plan, China will solidify its position as the world's largest innovative drug marketplace and will strive to achieve parity with the U.S. in original innovation [8]. - The integration of AI in healthcare is expected to grow significantly, with applications in clinical settings and drug development, indicating a trend towards more advanced healthcare solutions [9][11]. Investment Themes - Four core investment themes for the next decade are identified: 1. Original innovation in pharmaceuticals will be a key investment direction, potentially yielding high returns [10]. 2. The evolution of the Hong Kong Stock Exchange and the STAR Market will facilitate investment in innovative companies lacking immediate revenue or profits [10]. 3. The combination of AI and healthcare will lead to more practical applications, including AI-driven pharmaceuticals and home healthcare robots [11]. 4. As Chinese pharmaceutical innovation and international expansion continue, the market capitalization of leading companies may exceed one trillion, with the emergence of global multinational corporations [11].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不對因本公佈全部或任何部份內容而產生或因倚賴 該等內容而引致之任何損失承擔任何責任。 Duality Biotherapeutics, Inc. 本公司將於適當時候向本公司股東寄發通函及股東特別大會通告以及相關代表委 任表格。 承董事會命 映恩生物 董事會主席、執行董事兼首席執行官 朱忠遠博士 香港，2025年12月8日 映恩生物 （於開曼群島註冊成立的有限公司） （股份代號：9606） 股東特別大會的暫停辦理股東登記 映恩生物（「本公司」）董事（「董事」）會（「董事會」）謹此公佈將於2025年12月30日 （星期二）上午九時正假座中國上海市浦東新區櫻花路868號A座11樓董事會會議 室召開股東特別大會（「股東特別大會」）。 為釐定有權出席股東特別大會並於會上投票的股東身份，本公司將由2025年12月 23日（星期二）至2025年12月30日（星期二）（包括首尾兩日）暫停辦理股東登記手 續，在此期間亦不會辦理股份過戶登記手續。為符合資格出席股東特別大會及於 會上投票，所有股份過戶連同相關股 ...

Core Insights - The Chinese biopharmaceutical sector is experiencing a resurgence after a period of adjustment, with the industry overall rising by 16.72% from early 2025 to the end of November, outperforming the CSI 300 index by 1.68 percentage points [1] - The active business development (BD) transactions and breakthroughs in innovative drug development are key drivers behind this growth [1][2] - The focus on "second-generation technology paradigms" in biotech, such as advancements in antibody technology and CAR-T therapies, is expected to be a significant investment direction in the near future [1][2] Industry Trends - The Chinese biopharmaceutical industry is entering a new phase centered on original innovation and global competitiveness, with China projected to account for 10%-15% of new drug listings globally [4] - As of August this year, the number of external licensing agreements for 2025 has already matched the total for 2024, with a total value of $50 billion, surpassing the entire amount for 2024 [2] - The proportion of external licensing transactions from Chinese companies has exceeded 40%, with half of these involving next-generation therapies [3] Investment Opportunities - There is a significant amount of unmet clinical needs and untapped innovation space in the market, providing rich investment themes and potential for more BD cases [2] - The quality of companies and their growth potential are critical in determining their market value, regardless of temporary low valuations [2] - The collaboration between biotech firms and multinational corporations (MNCs) is increasing, with MNCs expanding their BD teams and establishing regular communication with Chinese biotech companies [3][6] Challenges and Considerations - The industry faces challenges such as the need for improved commercialization capabilities and the risk of resource wastage due to blind competition [4][5] - The pricing of Chinese biotech assets in overseas transactions is often perceived as low, which may hinder their global competitiveness [6] - The importance of establishing long-term trust and understanding international market rules is emphasized for achieving fair valuations in cross-border transactions [6][7] Strategic Insights - The essence of BD transactions lies in the synergy of capital, brand, and capability, which can significantly enhance a company's growth beyond short-term gains [6] - Companies must focus on quality improvement and differentiated innovation rather than merely competing on speed to avoid industry setbacks [4][5] - The investment strategy should consider long-term market dynamics and the potential future landscape of the industry [8]

Group 1 - In the first 11 months of the year, 626 out of 650 comparable QDII funds saw an increase in net value, representing 96.3% of the total [1] - The innovative pharmaceutical sector has rebounded, leading to significant gains for funds heavily invested in this area, with the top-performing fund, Huatai Fuhong Hong Kong Advantage Selection Mixed A/C, achieving a return of 141.57% [1] - The fund's investment strategy focuses on innovative drugs with global competitiveness and high barriers in the medical equipment sector [1] Group 2 - Nine QDII funds recorded gains exceeding 87% in the first 11 months, with four funds from E Fund Management achieving over 92% returns [2] - The top holdings of these funds include companies like Fuhong Hanlin, Xinda Biopharmaceutical, and Keren Biotech [2] - Other high-performing funds include Chuangjin Hexin Global Pharmaceutical Biotechnology Stock Initiation A and C, and GF CSI Hong Kong Innovative Medicine ETF, with returns of 100.32% and 99.68% respectively [2] Group 3 - The Industrial Bank New Economy Mixed Dollar fund, managed by Zhao Bei, has top holdings including Xinda Biopharmaceutical and Jinfang Pharmaceutical [3] - Funds focused on oil and gas, as well as real estate, have underperformed, particularly those tracking the FTSE Saudi Arabia Index [3] Group 4 - The top 10 QDII funds by performance in the first 11 months include Huatai Fuhong Hong Kong Advantage Selection Mixed A, with a return of 141.57%, and E Fund Global Pharmaceutical Industry Mixed C, with a return of 95.67% [4] - The performance of these funds highlights the strong returns in the pharmaceutical sector compared to other sectors like oil and real estate [4]

Core Insights - The article emphasizes that the Chinese innovative drug industry has significantly improved its systemic capabilities, leading to explosive growth in overseas business, with a transaction scale reaching approximately $100 billion in the first three quarters of 2025, including upfront payments of $5 billion [3][4] - The market is being activated by a series of major transactions, with companies like Kangfang Biotech, Hengrui Medicine, and Kelun Pharmaceutical making significant moves, resulting in a frenzied atmosphere in the Hong Kong IPO market [3][4] Innovative Drug Sector - China's innovative drug industry has a competitive edge over the U.S. in terms of R&D efficiency, costs, and clinical research, supported by a large clinical patient population and unique regulatory advantages [4] - The article draws parallels between the innovative drug sector and the semiconductor industry, suggesting that as traditional innovation approaches its limits, new technologies like dual antibodies and ADCs will become the core of innovation, leveraging China's industrial advantages [5] - Key factors for investment in innovative drugs include innovation, speed, and positioning, with companies needing to develop unique drug candidates or dominate specific niches to achieve profitability [6] Challenges in the Innovative Drug Market - Despite having the capability to develop original innovative drugs, the Chinese market is limited, leading companies to rely on overseas expansion, with only 3% of the global innovative drug market size compared to the U.S. [6][7] - Chinese innovative drug companies face challenges in late-stage clinical research capabilities and global commercialization, which are critical for competing in high-value markets like the U.S. [7][8] Biomanufacturing Sector - The biomanufacturing sector faces complexities, particularly in product selection, where over 90% of companies fail due to poor choices [9] - Successful biomanufacturing requires a focus on cost control, engineering capabilities, and commercial value, with a strong emphasis on collaboration among scientists, industry experts, and project managers [10][11] - The market size is crucial for biomanufacturing companies, as only those targeting trillion-level markets can potentially develop into leading enterprises [10] Investment Considerations - The article suggests that investment in innovative drugs and biomanufacturing should align with national strategies and market demands, emphasizing the importance of selecting companies that can create real value [11][12] - Investors should focus on identifying entrepreneurs with ambitious goals and the potential to lead in their fields, as well as being open to disruptive business models [13][14] - The investment landscape is characterized by a need for precision in selecting companies with core competitive advantages, as the barriers to entry are low but the potential for high returns is significant [14]

随着资本市场互联互通机制的持续完善，A股与港股之间"双向奔赴"的上市热潮正以前所未有的活力席 卷市场。 港股生物科技企业百奥赛图即将登陆科创板，成为2025年两地资本市场双向互动的又一标志性事件。从 港股公司"返乡"回A，到A股企业"出海"赴港，再到子公司分拆上市的跨市场布局，A+H上市生态正不 断丰富，不仅为企业开辟了多元化融资渠道，更推动内地与香港资本市场在资源配置、制度创新等层面 实现深度融合。 港股回A模式日益成熟 百奥赛图的回A之路并非个例。另一家港股公司映恩生物于11月完成科创板上市辅导备案，正式启动回 A进程。今年4月15日，映恩生物在港交所上市，此次IPO募资总额约2.43亿美元，共引入15名基石投资 者，均为头部国际长线资本、国内知名公募和知名药企，是近四年来港股18A板块募资规模最大的IPO 之一。 中国光大集团旗下实业旗舰企业光大环境则成为政策红利下的回A标杆，公司于11月14日公告拟发行不 超过8亿股，计划登陆深交所。光大环境为全球最大垃圾发电投资运营商，此次回A股募资将用于主营 业务拓展及补充营运资金，进一步巩固在固废处理、清洁能源等领域的领先地位，其成功上市有望为更 多大湾区港股企 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 映恩生物 (「本公司」) 呈交日期: 2025年12月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09606 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 200,000,000 | USD | | 0.0001 | USD | | 20,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 200,000,000 | USD | | 0.0001 | USD | | 20,000 | 本月底法定/註冊股本總額： ...

Group 1 - The Hang Seng Healthcare Index (HSHCI) has risen by 1.17% as of December 4, 2025, with notable increases in stocks such as InnoCare Pharma (up 4.91%), CanSino Biologics (up 4.65%), and MicroPort Scientific (up 4.51%) [1] - The 11th batch of national centralized procurement results was released on November 7, including 453 products across 55 varieties, with an average price reduction of approximately 75% compared to the highest valid bid [1] - The upcoming ESMO Asia 2025 conference will take place from December 5-7, and the 67th American Society of Hematology (ASH) meeting will be held from December 6-9, which are expected to catalyze data releases in the healthcare sector [1] Group 2 - The top ten weighted stocks in the Hang Seng Healthcare Index (HSHCI) account for 60.48% of the index, including companies like BeiGene, Innovent Biologics, and WuXi Biologics [2] - The Hang Seng Healthcare ETF (159557) closely tracks the HSHCI, providing a market reference for the performance of healthcare securities listed in Hong Kong [2] - Investors without stock accounts can access the Hong Kong healthcare sector investment opportunities through the Hang Seng Healthcare ETF linked fund (018433) [2]

尽管港股市场呈现调整，但是国信证券指出近期港股市场呈现小幅调整但板块分化明显的特征，并为2026年创造了较好的布局空间。 该券商还指出，站在布局明年的角度，有不少乐观的理由，包括：美联储持续降息将带来流动性的逐步宽松；AI的进步值得期待，26年有望更加广泛的AI 应用推出；汽车、半导体明年依然有较好的利润增长；外卖战有望在26年的某个时间趋缓；十五五规划落地带来的积极影响。 因此，国信证券认为恒生科技与恒生互联网的性价比已经初步体现。 今日市场 从市场表现来看，家电、煤炭、黄金等个股表现亮眼，而科技、医药、汽车股则出现调整。 家电股领涨市场 家电板块今日表现突出，创科实业(00669.HK)涨3.15%、海尔智家(06690.HK)涨0.90%、美的集团(00300.HK)涨0.61%。 | 代码 | 名称 | 最新价 | 涨跌额 | 涨跌幅 ◆ | | --- | --- | --- | --- | --- | | 02285 | 泉峰控股 | 19.790 | +0.730 | +3.83% | | 00669 | 创科实业 | 94.900 | +2.900 | +3.15% | | 02619 | 香 ...

Group 1 - The Hong Kong biotechnology sector experienced a widespread decline, with notable drops in several companies' stock prices [1] - Specifically, Gilead Sciences-B fell over 13%, while Sanofi-B dropped more than 10% [1] - Other companies such as Crystal Technology Holdings and Hualing Pharmaceutical-B also saw declines exceeding 6% [1] Group 2 - Gilead Sciences-B's latest price is 11.750, with a market capitalization of 116.56 billion and a year-to-date increase of 290.37% [2] - Sanofi-B's latest price is 7.000, with a market capitalization of 7.44 billion and a year-to-date increase of 102.31% [2] - Crystal Technology Holdings has a latest price of 9.330, a market capitalization of 401.48 billion, and a year-to-date increase of 56.02% [2] - Hualing Pharmaceutical-B's latest price is 3.230, with a market capitalization of 34.13 billion and a year-to-date increase of 121.23% [2] - Other companies like Wangshan Wangshui-B and Sanleaf Biotech-B also reported significant declines, with year-to-date increases of 123.25% and 920.75% respectively [2]